Belite Bio Inc. ADR

Belite Bio presented Phase III data on Tinlarebant at the Morgan Stanley Healthcare Conference, showing a 36% slowdown in progression of DDAF lesions in Stargardt patients over two years versus placebo and a favorable safety profile. The FDA is reviewing the submitted approval application via the accelerated pathway with a PDUFA date of February 12; parallel applications are underway in Japan and a separate Phase III program is ongoing for geographic atrophy. The company is preparing commercial and education efforts for retinal specialists and expects payers to be receptive to rare-disease pricing. » More on de.investing.com

Belite Bio presented data and the regulatory pathway for Tinlarebant at a specialist conference; the drug is in a prioritized review with the FDA and in Japan under the Sakigake designation. The DRAGON study showed a 36% slowdown in DDAF lesion growth and supportive signals in secondary analyses as well as in the fellow eye. Safety events such as xanthopsia and delayed dark adaptation were described as manageable and, according to management, decrease over time. The company is preparing for market launch with physician training, genetic test support, payer engagement, and patient support. » More on de.investing.com

The FDA has accepted the tinlarebant marketing application for priority review and set a PDUFA date of February 12, 2025. The phase III DRAGON study showed a 36% efficacy signal in slowing lesion growth with a company-reported favorable safety profile. Belite Bio reports strong payer support, is preparing a launch program targeting about 100 specialists, and is concurrently advancing a phase III program in geographic atrophy (interim analysis expected late 2024/early 2025). However, the company still needs to overcome final regulatory and commercial hurdles before any revenue can be realized. » More on de.investing.com